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General considerations. Since the 1950s there has been a
small, steady stream of publications from around the world
describing the occurrence of heart-reactive antibodies in
patients with myocarditis and idiopathic dilated cardiomy-
opathy (1-8) . Early reports were based largely on immuno-
histopathologic findings while more recent reports, such as
that by Latif et al . (9) in this issue of the Journal, identify
specific cardiac autoreactivity at the molecular level . Coin-
cident with these clinical investigations, experimental stud-
ies in rodents have demonstrated that cardiotropic viral
infections or autoimmunization with cardiac antigens may
elicit myocardial injury leading to cardiomyopathy, with
concomitant development of heart-reactive antibodies and
T cells (10-12). Unfortunately, the animal models and clin-
ical observations in humans have yet to establish that dilated
cardiomyopathy is an immune-mediated syndrome nor has
there been an unequivocal demonstration that the presence
of autoantibodies is related to the clinical manifestations of
the disease . The purpose of this discussion is to review the
critical components of the debate regarding the role of
autoimmunity in idiopathic dilated cardiomyopathy .
Over the past 25 years, as the sensitivity and specificity of
immunoassays have improved, immunologists have found
that sera from the majority of normal humans with no clin-
ical illness contain reactivity against a variety of self-
constitutents including myocardial proteins . Therefore, if
normal persons have heart-reactive antibodies, do patient3
with idiopathic dilated cardiomyopathy and myocarditis
have more, and what is the relevance of these antibodies to
the disease process? From a technical perspective, most
studies describing the presence of autoantibodies in idio-
pathic dilated cardiomyopathy and myocarditis have relied
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on qualitative or semiquantitative evaluation of Western
blotting or immunohistochemical procedures to demonstrate
the presence of heart-reactive antibodies
. In the absence of
rigorous quanttation, the distinction between patient groups
and control subjects has been difficult to assess and has often
been confounded by unresolved questions of specificity .
In immunologic terms, a critical issue concerning studies
of the autoimmune basis of human idiopathic dilated cardio-
myopathy involves our ability to identify the self-antigens
that are the targets of long-standing immune responses and
the mechanisms that initiate such responses . In addition, we
must be able to define and distinguish the self-responses that
induce tissue damage from those that occur as a secondary
manifestation of an ongoing pathologic process and are, as
such, epiphenomena . Conventional wisdom suggests that
autoantibodies in idiopathic dilated cardiomyopathy result
from exposure of the immune system to normally seques-
tered cardiac tissue proteins released from injured myo-
cytes. One appealing hypothesis is that in idiopathic dilated
cardiomyopathy, previously undetected myocardial injury
gives rise to heart-reactive antibodies or T cells, or both . But
if myocardial injury alone is capable of initiating an autoim-
mune response, why do we not see autoimmune myocardial
disease after myocardial infarction? The answer probably
lies in the observation that intracellular antigens, such as
those released by irreversibly injured cells, are not immuno-
genic by themselves . For such antigens to become immuno-
genic, there is a requirement for the addition of an adjuvant .
One such a scenario might be a cardiotropic viral infection
that could act as an adjuvant by stimulating local cytokine
secretion and the activation of antigen presenting cells .
Viruse3 are well known for their immunomodulatory activi-
ties and, indeed, the ultrasensitive techniques of molecular
biology have facilitated the documentation of the presence of
enteroviral sequences in cardiac tissues of patients with
idiopathic dilated cardiomyopathy (13,14), although the sen-
sitivity and specificity of such techniques are currently the
subject of intense debate (15) .
Putative autoantigens in idiopathic dilated cardiomyopa-
thy . For heart immunoreactivity to have diagnostic or prog-
nostic significance, it is critical to establish the antigenic
specificity of the reactivity . Among the cardiac proteins that
have so far been identified as the putative autoantigens,
those that have received the greatest attention are the
adenine nucleotide translocator (ANT), the branched chain
alpha ketoacid dehydrogenase (BCKD) complex, the beta-
adrenergic receptor and myosin . The recent findings of Latif
et al . (9) in this issue of the Journal implicate several other
structural proteins and include the heat shock protein
(HSP)-60 molecule . Why do many patients with idiopathic
dilated cardiomyopathy produce antibodies to these and
other antigens? One hypothesis is that exaggerated immune
responses to many of these proteins may be part of a
generalized immune regulatory disorder . The possibility that
these patients may be genetically predisposed toward im-
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mane regulatory dysfunction has been suggested by genetic
studies demonstrating that patients with idiopathic dilated
cardiomyopathy have an increased frequency of certain
HLA class Ii phenotypes (16), particularly among those
found to have antiheart antibodies (17) .
The myocyte as an antigen presenting cell . Can the myo-
cyte present antigen, thereby initiating a cascade of cellular
and molecular events leading to autoimmunity to cardiac
antigens? This concept has recently been questioned by in
vitro experiments demonstrating that human myocytes, even
when experimentally induced to express MHC antigens, fail
to induce activation and proliferation of allogeneic cells (18) .
These results suggest that the myocyte may be a poor
antigen-presenting cell
. One possible explanation for this is
that myocytes appear to lack the critical costimulatory
molecules required for activation and proliferation of T cells
(19) . Although further studies are clearly needed to define
whether productive immune interactions do indeed occur
between T cells and myocytes, at face value it appears that
cardiac myocytes may be immunologically inert . How does
one then reconcile possible autoimmune myocyte injury? It
is conceivable that such injury results from 1) the direct
effects of antibodies bound to antigen-expressing myocytes ;
2) the release of cytokines produced by infiltrating T cells
and professional antigen-presenting cells present in the mi-
lieu, such as dendritic cells and macrophages ; or 3) a
combination of the two .
The potential role of antibodies In cardiac tissue injury .
Since most of the proteins that have been identified as
cardiac autoantigens are intracellular, it is difficult to envi-
sion how antibodies to these intracellular antigens would be
able to damage normal myocytes. Two schools of thought
have since emerged. One specifies that after an autoimmune
response is initiated, circulating autoantibodies to intracel-
lular antigens cross-react with native membrane cardiac
tissue proteins. Thus, following even a small amount of
myocardial injury (possibly initiated by a cardiotropic viral
infection), an antibody response that affects nos .nal myo-
cytes could lead to global myocardial dysfunction. This
concept is supported by the observation that antibodies
against the intracellular mitochondrial ANT protein cross-
react with myocyte sarcolemmal calcium ion (Ca 2+) channel
proteins (20) . Binding of Ca--+ channel proteins by such
cross-reactive antibodies can thus physiologically alter the
metabolism of normal myocytes, possibly leading to myo-
cyte injury.
The other viewpoint suggests 'hat myocytes may present
self-peptides within the context of induced MHC antigen
expression. Immune responses are initiated by the recogni-
tion of antigens in the form of peptides processed by cells
and presented to the T cell receptor by major histocompat-
ibility (MHC)-peptide complexes . Thus, if myocytes are to
be
recognized by the immune system, they must process and
present self-immunogenic peptides complexed with MHC
molecules on their cell surfaces. Normal human cardiac
myocytes do not express detectable levels of MHC class II
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antigens (21), and their constitutive expression of MHC class
I molecules is still a subject of debate . However, myocardial
inflammation, such as that induced during viral myocarditis
or during episodes of rejection in the transplant setting,
results in a marked increase in both the level of class I and
class 11 antigens expressed by these cells (22-24) . Perhaps
more important for the discussion at hand, increased MHC
expression on myocytes has also been described in endo-
myocardial biopsy samples from subgroups of patients with
idiopathic dilated cardiomyopathy (25,"6) . It is thus conceiv-
able that in the setting of a number of myocardial alterations
(infectious, chemical, biochemical, and so forth), native
self proteins are intracellularly processed by such myocytes,
complrxed with these MHC molecules and presented to
infiltrating T cells . This process then may initiate the cascade
of immune dialogue, resulting eventually in progressive
myocyte damage .
In support of this concept, recent studies of tissue from
patients with both myocarditis and idiopathic dilated cardio-
myopathy have identified increased expression of intracellu-
lar antigens such as ANT and BCKD. In addition, these
intracellular antigens may be aberrantly expressed on the
surface of myocytes (25) . Studies in experimental post-
coxsackievirus autoimmune myocarditis have shown that
immunoglobulin G antibodies, which are bound to myocytes
throughout the myocardium, were specific for intracellular
antigens (27) . Additionally, one of the interesting findings by
Latif et al . (9) in this issue of the Journal was the documen-
tation that sera from a high frequency of patients with
idiopathic dilated cardiomyopathy recognize one family of
heat shock proteins, the HSP-60. This suggests that myocyte
injury induces the expression of HSP-60 or other stress
proteins that may have immunomodulatory activities and
could influence the development and course of autoimmune
recognition of the myocardium .
The potential role of cytoknes in cardiac tissue injury .
The concept that a localized exaggerated immune response
may result in myocyte injury secondary to in situ activation
and release of cytokines is particularly appealing in myocar-
ditis, In this context, studies have shown that treatment of
coxsackievirus-infected mice with the polyclonal mitogen
lipopolysaccharide or with the cytokines tumor necrosis
factor-alpha or interleukin 1-beta, markedly exaggerates the
pathogenic process of myocyte injury (28) . In addition, a
growing number of studies describe various cytokine effects
on intact myocardium (29,30) and cu isolated myocytes (31) .
These data all support the view of an important contributing
role of cytokines in immune-mediated cardiac tissue injury .
Such arguments are easily applied to myocarditis and, al-
though they may also apply to cardiomyopathic hearts, it is
difficult to reconcile them with the absence of infiltrating
cells in idiopathic dilated cardiomyopathy . One intriguing
hypothesis is that within the setting of previously undiag-
nosed cardiac inflammation, released cytokines and growth
factors not only could affect myocytes, but also could play a
critical role in modulating the secondary development of
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myocyte hypertrophy and interstitial fibrosis ChaF,tcteristic
of idiopathic dilated cardiomyopathy .
Unanswered questions . To accept the hypothesis that auto-
immune effector mechanisms play a major role in the initiation
and perpetuation of cardiac tissue dysfunction in idiopathic
dilated cardiomyopathy, one has to address the following
issues : I) Are the target antigens expressed on the myocyte
surface normal sarcolemmal constituents or abnormally ex-
pressed intracellular proteins? 2) Are the target antigens in fact
peptides of processed self-proteins that are expressed in the
form of peptide-MHC complexes on the cell surface during
periods of inflammation caused by viral or biochemical insult,
or both? If so, can they initiate productive immune injury?
3) Are tissue-hound antibodies specifically reactive with these
antigens?, and 4) Do antigen-specific, lissu .--hound antibodies
alter myocyte function? Without these data, it will remain
difficult to prove the hypothesis that ongoing myocardial dys-
function in idiopathic dilated cardiomyopatlig= is modulated by
outwiritibodics .
Conclusions. Human idiopathic dilated cardiomyopathy
is probably a multifaceted disease, with multiple etiologies
that result in progressive myocyte injury . Conceptually, it is
appealing to hypothesize that a subgroup of patients with
idiopathic dilated cardiomyopathy have an immune-
mediated disease . It is plausible that persistent circulating
autoanlibodies are markers of ongoing myocardial injury,
although the presence of autoantibodies does not necessarily
signify that they play a specific role in pathogenesis . The
hypothesis that heart-reactive antibodies are responsible for,
or contribute to, the clinical signs and symptoms associated
with cardiomyopathy is as yet unproved . Because antibodies
freely diffuse through intercellular spaces, one might postu-
late that they hind to cell surface moieties, e .g . calcium
channels, thus leading to impaired cardiac function . One
might further speculate that because heart-reactive antibody
profiles differ among patients, antibodies binding to other
surface moieties elicit similar changes in contractile func-
tion . From a practical perspective, the presence of circulat-
ing autoantibodies will likely remain the simplest method of
identifying patients with idiopathic dilated cardiomyopathy
who have a possible iminune disorder . It is critical, though,
to develop sensitive quantitative assays that focus on auto-
antibodies that are not only cardiac-specific but disease-
specific to idiopathic dilated cardiomyopathy . Only then will
studies of this subgroup of patients with idiopathic dilated
cardiomyopathy be meaningful and support the development
of rational therapies .
References
1 . Maisch B. Dog P. Lichau G . Kochsick K
. Diagnostic relevance of
humoral and cytotoxic immune reactions in primary and secondary
dilated cardinmyopathy
. Am J Cardiol 1983 :52 :1072-9 .
2 . Neumann DA, BLu-ck CL. Baughman KL
. Rose NR. Herskowitz A .
Circulating heart-reactive antibodies in patients with myocarditis or
cardiomyopathy
. J Am Coll Cardiol 1990 :16:839-46 .
3 . Caforio ALP, Bonifacio E, Stewart JT, et al
. Novel organ-specific
€HERSKOWITZ ET At
. .
EMTORIAI
. COMMENT
1387
circulating cardiac autoantibodies in dilated cardiomyopathy
. J Am Colt
Cardiol 1990 :15 :1527-34 .
4 . Caforic, ALP, Grazzini M . Mann JM
. et al . Identification of alpha and
beta-cardiac myosin heavy chain isoforms as major autoantigens in
dilated cardiomyopathy
. Circulation lq92 ;85 :1734-42 .
5 . Schultheiss H-P. Bolte HD
. Immunological analysis of auto-antibodies
against the adenine nucleotide translocator in dilated cardiomyopathy
.
J Mol Cell Cardiol 1985 .17
:603-17 .
6 . Limas CJ, Goldenberg IF
. Limas C . Autoantibodies against beta-
adrenoceptors in human idiopathic dilated cardiomyopathy
. Circ Res
1989 -.64 :97-103 .
7 . Ansari AA, Herskowitz A, Danner DJ
. Identification of rnilochondriA
proteins that serve as targets for autoimmunity in iouman dilated cardio-
myopathy . Circulation 1988
;78 Suppl :457.
8
. Wolff PG, Kuhl U, Schultheiss H-P . Laminin distribution and autoanti-
bodies to laminin in dilated cardiomyopathy and myocarditis
. Ain Heart J
1989 :117 :1303-9 .
9 . LWW N, Baker
CS, Dunn MA Rose ML. Brady P, Yacoub MH,
Frequency and specificity of antihearl antibodies in patients with dilated
caf(liomyopathy detected using SDS-PAGE and Western blotting . J Am
Coll Cardiol 1993 :22 :1378-84
.
10 . Alurez Fl, Neii N, Rose NR, Craig ST Beiwl KW . licart-specific
arutuantihodies induced by coxsackievirns B3 identification of heart
autoantigens
. Clin Immunol Immunopathol 1987 :43 :129-39,
It . Neu N, Rose NR . Beisel KW . Herskowitz, A, (
;urri-Glass G, Craig SW
.
Cardiac myosin induces myocarditis in genetically predisposed mice .
J Immunol 1987 :139 :1630-6.
12 . Smith SC . Allen PM . Myosin-induced acute myocarditis k a T cell
mediated disease
. J Immunol 1991 :147 :2141-7.
13 . Bowles NE, Richardson PJ. Olsen EGJ, Archard LC . Detection of
coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples
from patients withh myocarditis and dilated cardiomyopathy . Lancet
1986 ;1 :1120-3 .
14 . Kando!f R, Kirschner P . Ameis D. et al . Enteroviral heart disease
:
diagnosis by in situ hybridization . In : Schultheiss HP, editor. New
Concepts in Viral Heart Disease . Berlin : Springer-Aferiag, 1988 :337-48 .
15 . Weiss LM, Liu XF . Chang KL, Billingham ME . Detection of enteroviral
RNA in idiopathic dilated cardiomyopathy and other human cardiac
tissues
. J Clin Invest 1992
:90 :156-9 .
16 . Carlquist JF . Menlove RL . Murray MR, O'Connell JR . Anderson JI_,
HLA class 11 (DR and DQ) antigen associations in idiopathic dilated
cardiomyopathy, Circulation 1991
:83 :515-22 .
17 . Limas CJ, Limas C, Kubo SH, Olivari MT . Anti-beta-receptor antibodies
in human dilated cardioniyopathyanJ correlation with HLA-DR antigen% .
Am J Cardiol 1990
:65 :483-7 .
18. Ansari AA, Kanter K, Wang YC, Mayne A, Sell KW
. Herskowitz A .
Major histocompatibility complex-expressing human cardiac myocytes
are not the direct target of host cardiac-infiltrating cells : evidence for a
prominent role of the indirect pathway in human cardiac allograft rejec-
tion, Transplant Proc 1993
:25 :89-93 .
19. Ansari AA, Sundstrom JR, Runnels H
. et al . Absence of constitutive and
induced expression of critical cell-adhesion molecules on human cardiac
myocytes : role in transplant rejection . Transplant 1993 .
In
press .
20. Monad M
. Davies NW, Ulrich G, Schultheiss H-P . Antibodies against
ADP-ATP carrier enhance Ca2+ current in isolated cardiac myocyles .
Am J Physiol 1998 :255 :H960-4 .
21 . Rose ML, Coles MI . Griffin RJ
. Pomerance A, Yacoub MH . Expression
of class I and class II major histocompatibility antigens in normal and
transplanted human heart
. Transplant 1986 :41 :776-80 .
22 . Herskowitz A . Ansari AA
. Neumann DA, et al . Induction of major
histocompalibility complex (MHC) antigens within the myocardium of
patients with active myocarditis
: a nonhistologic marker of myocarditis .
J Am Coll Cardiol 1990
:15 :624-32 .
23 . Ansari AA, Tadros TS, Knopf WD. e
t al, Major histocompalibility
complex class I and class 11 expression by myocytes in cardiac biopsies
posttransplantation, Transplant 1988
:45 :972=8 .
24
. Wang YC. Herskowitz A, Go LB . et al
. Influence of cytokines and
immunosuppressive drugs
on major histocompatibility complex class 1/11
expression by human cardiac myocytes in vitro . Hum Imiatinol 1991
:31 :
1-11 .
25 . Ansari AA
. Wang Y-C, Danner DJ
. et al . Abnormal expression of
histoLompatibility and mitochondrial antigens by cardiac tissue from
1388
	
HERSKOWITZ ET AL .
EDITORIAL COMMENT
patients with myocarditis and dilated cardiomyopathy . Am J Pathol
1991 ;139:337-54 .
26
. Herskowitz A, Baughman KL, Rose NR, Neumann DA, Beschorner WE .
Induction of major histocompatibility antigens on myocardial cells in
patients with active myocarditis and idiopathic cardiomyopathy . In Ref
14:312-24 .
27 . Neumann DA, Lane JR, Lafond-Walker A . et al . Heart-specific autoanti-
bodies can be eluted from the hearts of Coxsackievirus B3-infected mice .
Clin Exp Immunol 1991 ;86:44J5-12 .
28
. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR.
JACC Vol. 22, No . s
November 1, 1993 :1385-8
Interleukin I or tumor necrosis factor can promote coxsackievirus
B-3-
induced myocarditis in resistant 810.A mice. J Exp Med 1992;175 :1123-9.
29 . Finkel MS, Oddis CV, Jacob TD, Watkins SC, Rattler BG, Simmons RL .
Negative inotropic effects of cytokines on the heart
mediated by nitric
oxide . Science 1992 :257 :387-9.
30
. Zhang J, Yu Z-X, Hilbert SL, et al . Cardiotoxicity of human recombinant
interleukin-2 in rats : a morphological study. Circulation 1993;87:1340-53
.
31 . Gulick T . Chung ML, Pieper SJ . Lange LG, Schreiner GF.
Interleukin I
and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic
respon-
siveness. Proc Nati Acad Sci USA 1989 ;86
:6753-7
.
